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The infiltration of leukocytes is a spe-
cific, rather than a random, event, and
regulated by the production of chemoat-
tractants that specifically attract a cer-
tain type of leukocytes. By early 1980s,
chemoattractants, now referred as “classi-
cal chemoattractants,” including the bac-
terial peptide N -formyl-methionyl-leucyl-
phenylalanine (FMLF), the C5a frag-
ment of serum complement and the
lipid mediator leukotriene B4 (LTB4),
had been identified. However, FMLF and
C5a lacked cell specificity and attracted
both neutrophils and monocytes. LTB4
exhibited both chemotactic and chemo-
kinetic activities for phagocytes. There
were several reports suggesting the exis-
tence of other cytokine-like chemoattrac-
tants. Lymphocyte-derived chemotactic
factor (LDCF) was detected in the culture
supernatant of mitogen-activated periph-
eral blood mononuclear cells (PBMC)
(1). A neutrophil chemoattractant was
also present in the culture supernatant of
activated monocytes or macrophages (2).
However, these cytokine-like chemoattrac-
tants were not purified or cloned.
The early 80s was the time when vari-
ous cytokines were finally purified and/or
cloned by immunologists owing to the
technological advance in protein purifica-
tion and molecular cloning. The labora-
tory of Joost J. Oppenheim was focused on
investigations of interleukin 1 (IL-1) and
established that it was produced by many
cell types and had multiple biological activ-
ities by also stimulating a great variety of
cell types. Subcutaneous injections of IL-1
had been shown to induce acute inflam-
matory responses with rapid margination
of neutrophils followed by their extravas-
cular infiltration (3). They therefore tested
the chemotactic effects of partially purified
human epithelial cell-derived thymocyte-
activating factor (ETAF); an epithelial cell-
derived IL-1. ETAF purified by elution
from Sephadex gels was found to attract
both polymorphonuclear and mononu-
clear leukocytes in vitro (4). Since ETAF
was biochemically identical to IL-1, it
was concluded that IL-1 was chemotac-
tic. These findings were confirmed by
Dinarello and his colleagues (5). In addi-
tion to IL-1, recombinant human TNF was
shown to be chemotactic for neutrophils
by another group (6). These findings sug-
gested that cytokine-like chemoattractants
produced by activated mononuclear leuko-
cytes reported earlier could be attributed
to IL-1 and/or TNF. However, the Oppen-
heim laboratory was concerned about the
fact that their preparations of ETAF/IL-
1were not pure and pursued opportunities
to investigate more purified preparations of
IL-1 (personal communication with Joost
J. Oppenheim).
I studied inflammation in Hideo
Hayashi’s laboratory in Kumamoto, Japan
from 1979 to 1985. My research was
focused on three putative macrophage
chemoattractants partially purified from
skin extracts of guinea pig delayed hyper-
sensitivity reaction, one of which was
thought to be the guinea pig version of
LDCF. Unfortunately, it was never purified
to determine its identity. I met Ed Leonard
in 1984 when he came to Japan to attend
The 10th International Reticuloendothe-
lial System Congress. His lab was interested
in identifying the nature of chemoattrac-
tants derived from activated mononuclear
leukocytes or bacteria. He expressed his
interest in our guinea pig chemoattractants
and recruited me to join his laboratory.
In 1985, I completed my PhD project and
came to Ed’s lab on a fellowship supported
by the Japanese Foundation for Promo-
tion of Cancer Research. I brought par-
tially purified guinea pig LDCF to study,
but that plan was immediately scratched
when Ed and Tibor Borsos, chief of our
lab, found out that guinea pig skin was
treated with acetone before protein extrac-
tion. They were concerned about possible
artifacts due to acetone treatment.
We were very much experienced in eval-
uating the activity of chemoattractants by
examining their potency and efficacy using
the 48-well multi-well chemotaxis cham-
bers developed by Ed (7) (Figure 1). In
1986, I published my first paper in Ed’s
lab examining the oxidation of FMLF by
neutrophils and I was ready for a larger
task. Since we were very intrigued to learn
that the cytokine IL-1 was chemotactic for
neutrophils and monocytes, we decided to
examine the chemotactic activity of IL-1
in more detail. In collaboration with the
Oppenheim lab, we examined the chemo-
tactic activity of highly purified native IL-
1 or recombinant IL-1. To our surprise,
neither of them was chemotactic for neu-
trophils or monocytes. We speculated that
IL-1 might indirectly attract neutrophils
by inducing the release of a chemoattrac-
tant such as LTB4 by neutrophils. We tested
this hypothesis, but there was no chemo-
tactic activity in the supernatant of IL-1-
stimulated neutrophils. We also examined
whether IL-1 could augment neutrophil
migration induced by other chemoattrac-
tants, such as FMLF, or activate basophils
to release neutrophil chemoattractants.
Again, IL-1 showed no effects. These results
led us to conclude that the partially puri-
fied IL-1 preparation was contaminated by
a neutrophil chemoattractant, which was
different from IL-1. The supernatant of
LPS-activated PBMC or monocytes, which
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FIGURE 1 | A chemotaxis assay system used to purify MDNCF.
(A) Previously used individual chemotaxis chamber (left) vs. 48-multi-well
chemotaxis chamber (right). (B) Consecutive fractions eluted from a
reversed-phase HPLC column were assayed in duplicate at two different
dilutions (1:1000 and 1:3000) in a single chamber with a negative (buffer) and
positive (FMLF) control, and migrated cells on the bottom of the filter were
stained (from the original notebook). The fraction 38 had the peak activity.
(C) The percentage of migrated cells was analyzed using an image analyzer.
are rich sources of IL-1 and used as a
source of partially purified IL-1, indeed
also contained a potent neutrophil chemo-
tactic activity, further supporting our con-
clusion (8).
Kouji Matsushima, head of a group in
the Oppenheim lab, had a vast knowl-
edge and experience in protein purification
and had just succeeded in purifying IL-1.
Because the Leonard and the Oppenheim
lab were both interested in identifying the
protein, which contaminated crude IL-1
preparations, Kouji and I quickly estab-
lished collaboration and decided to bio-
chemically identify this activity. Since we
were both from Japan, we had no lan-
guage barrier. We first isolated neutrophil
chemotactic activity from IL-1 activity con-
tained in the culture supernatant of LPS-
activated PBMC (8), and then achieved
the first purification by the end of 1986.
This protein was the first chemoattractant
with target cell specificity and we termed
the protein monocyte-derived neutrophil
chemotactic factor (MDNCF) based on its
activity and cellular source (9).
The N-terminal amino acid sequence
of MDNCF was determined in Ettore
Appella’s laboratory, NCI. It was real-
ized that MDNCF exhibited considerable
amino acid sequence similarity at the
N-terminus to β-thromboglobulin (β-TG),
platelet factor 4 (PF4), and γIP-10. The
β-TG precursor CTAPIII (connective tis-
sue activating protein) stimulated repli-
cation of connective tissue cells, suggest-
ing its role in wound healing. PF4 was a
chemoattractant.γIP-10 was an interferon-
induced product of the U937 monocyte-
like cell line. Thus, MDNCF not only struc-
turally but also functionally belonged to
this family of small proteins involved in
inflammation (9). β-TG, PF4, and γIP-
10 were subsequently determined as the
members of the chemokine family (10).
When we submitted our manuscript to a
journal for publication, we had consider-
able difficulty overcoming the criticisms of
one of the reviewers, who maintained that
detection of a cell-derived chemoattrac-
tant for neutrophils was redundant with
already well known chemotactic factors
such as FMLF and C5a, and was there-
fore not of any importance. It has recently
become clear that a signal relay of multiple
chemoattractants is critical for the precise
trafficking of leukocytes to sites of tissue
injury (11); thus, chemoattractants have a
non-redundant role.
Shortly after the publication of our
report in 1987, the laboratories of Marco
Baggiolini and Jo Van Damme also
reported the purification of the identi-
cal protein (12, 13). At a meeting in
Baden, Austria, it was agreed by the
co-discoverers of this cell-derived neu-
trophil chemoattractant to name this activ-
ity neutrophil-activating peptide (NAP-1).
However, Larsen and coworkers in the
Oppenheim’s laboratory subsequently dis-
covered that NAP-1 also chemoattracted a
subset of T lymphocytes and they therefore
proposed to rename it as interleukin-8 (IL-
8) (14). Although this proposal was even-
tually accepted, it was disliked by the inter-
leukin aficionados because they did not
consider chemotactic effects very impor-
tant (personal communication with Joost
J. Oppenheim).
During the purification of MDNCF, we
noticed that a monocyte chemoattractant
was also present in the culture supernatant
of LPS-activated PBMC. However, purifi-
cation of the monocyte chemoattractant
was more difficult because the amount of
this chemoattractant in the supernatant
was lower than that of MDNCF. Subse-
quently, both the Leonard and the Oppen-
heim laboratories independently puri-
fied the protein, monocyte chemoattrac-
tant proten-1 (MCP-1) or macrophage
chemotactic and activating factor (MCAF),
respectively, from the culture supernatant
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of tumor cell lines and published a paper
in 1989 (15, 16). We believed that MCP-
1 was identical to LDCF. Unexpectedly,
amino acid sequence analysis of this MCP-
1 revealed the presence of four half cys-
teine residues at almost identical loca-
tions to those of MDNCF, although the
overall amino acid sequences between
the two proteins were not highly con-
served. There was no extra amino acid
between the first two half cysteine residues
in MCP-1 (CC vs. CXC). By this time,
there were reports of additional proteins
belonging to this protein family, includ-
ing RANTES, pLD78, TCA3, MIP, and
JE. Although these proteins were later
determined as chemokines (JE turned out
to be the mouse ortholog of human
MCP-1) (10), MCP-1 was the only pro-
tein identified based on its biological
capacity to selectively attract monocytes.
Identification of IL-8 and MCP-1 thus
pointed out the existence of a family
of chemotactic cytokines with leukocyte
specificity and led to the identification
of the protein family chemokines with
at least two CXC and CC subgroups.
This family was subsequently referred
to as chemokines, an abbreviated ver-
sion of “chemoattractant cytokines,” by
Oppenheim.
As noted above, we began our study by
asking a simple question whether IL-1 was
indeed a chemotactic factor. The results
of the study led us to the discovery of
IL-8, the first cytokine-like chemoattrac-
tant with cell specificity, and most impor-
tantly, which in turn led to the discovery
of a novel protein family with chemotactic
activity. This was an example of a suc-
cessful collaboration between two labora-
tories with complementary strength. We
were extremely fortunate to be the first
to identify IL-8 and MCP-1 as evidenced
by being awarded the patents for each,
because the field was ripe for the dis-
covery and many laboratories were just
behind us.
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